The Listing Document and the documents incorporated by reference are posted on Lundbeck’s webpage (https://www.lundbeck.com/global/investors/the-share/new-share-structure).
The dual-share structure – including an expected timetable – is described in more detail in the Listing Document and in the notice convening the extraordinary general meeting to be held.
|Vice President, Investor Relations|
|[email protected]||[email protected]|
|+45 30 83 24 26||+45 30 83 30 24|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES STATES,
THIS PRESS RELEASE IS NOT AN OFFER TO SELL OR AN INVITATION TO PURCHASE OR SUBSCRIBE, OR A SOLICITATION OF AN OFFER TO BUY OR SUBSCRIBE, FOR SECURITIES.
THE REGISTRATION DOCUMENT HAS BEEN DRAWN UP SOLELY TO COMPLY WITH LUNDBECK’S OBLIGATIONS UNDER APPLICABLE DANISH SECURITIES LAW AND REGULATIONS TO EFFECT THE SPLIT OF THE SHARES. THE OFFERING DOCUMENT CANNOT BE REFERRED TO FOR ANY PURPOSES OTHER THAN THE SPLITTING OF SHARES.
Lundbeck is a global pharmaceutical company specializing in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are relentlessly dedicated to restoring brain health, so that everyone can perform at their best. We are committed to fighting stigma and discrimination against people with brain conditions and advocating for wider social acceptance of people with brain conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline focuses on developing transformative treatments for brain diseases for which there are few or no treatment options.
For more information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram (h_lundbeck), Twitter at @Lundbeck and via LinkedIn.
Third Party Information, Legends, and Safe Harbor/Forward-Looking Statements
This corporate statement may include third-party statements or references to third-party information. To the extent that information from third parties arises directly from this document, the company can confirm that the information has been faithfully reproduced, but the company can give no assurance as to the accuracy of the information or the forward-looking statements contained in these statements. coming. in existence. To the extent that the company makes reference to third party information, including a reference to the
None of the securities referred to herein have been or will be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of a state or other jurisdiction in
This corporate news release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward-looking statements include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as “believe”, “anticipate”, “expect to”, “estimate”, “intend”, “plan”, “project”, “will”, “continue”, “result”, “could”, “may”, “might”, or any variation of these words or other words with similar meanings. All statements other than statements of historical fact included in this presentation, including, without limitation, those regarding our financial condition, business strategy, management plans and objectives for future operations (including plans for development and objectives relating to our products), are forward-looking statements.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could affect future results include, but are not limited to, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, breaches of contract or unexpected terminations, government-mandated or market-driven price reductions for Lundbeck’s products, introduction of competing products, Lundbeck’s ability to successfully market new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation, and unexpected growth in costs and expenses.
Forward-looking statements contained in this document and oral presentations made on behalf of Lundbeck speak only as of the date of this presentation. Lundbeck undertakes no obligation to update or revise any forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, or to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relationship to actual results, unless otherwise required by applicable law or stock exchange regulations.
Ottiliavej 9, 2500 Valby,
+45 3630 1311
(c) Decision 2022. All rights reserved., sources